The not-so-terrible challenge for future trials of COVID-19 therapeutics
Several companies, including Pfizer, are developing antiviral drugs that could halt the progression of COVID-19 symptoms or prevent the onset of disease for close contacts of people with infections. Theoretically, the therapeutics would be another tool used to fight the coronavirus alongside vaccines.
Former Food and Drug Administration Commissioner Scott Gottlieb is confident there will be some successes, noting that the coronavirus isn't "a hard virus to drug in terms of how it replicates." But there is a bit of a race against the clock on this issue, although the reason for that probably won't be the worst thing you've heard since the pandemic began.
It's becoming more difficult to find "virus naive" patients in the United States, Gottlieb said during an appearance on MSNBC's Squawk Box on Monday. Because so many people have either been vaccinated or had a previous infection, it's increasingly challenging to find enough people who don't have some form of immunity to enroll in trials to determine the efficacy of the drug treatments. Watch Gottlieb's explanation below.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Band Aid 40: time to change the tune?
In the Spotlight Band Aid's massively popular 1984 hit raised around £8m for famine relief in Ethiopia and the charity has generated over £140m in total
By Rebekah Evans, The Week UK Published
-
Starmer vs the farmers: who will win?
Today's Big Question As farmers and rural groups descend on Westminster to protest at tax changes, parallels have been drawn with the miners' strike 40 years ago
By The Week UK Published
-
How secure are royal palaces?
The Explainer Royal family's safety is back in the spotlight after the latest security breach at Windsor
By Chas Newkey-Burden, The Week UK Published
-
ACA opens 2025 enrollment, enters 2024 race
Speed Read Mike Johnson promises big changes to the Affordable Care Act if Trump wins the election
By Peter Weber, The Week US Published
-
McDonald's sued over E. coli linked to burger
Speed Read The outbreak has sickened at least 49 people in 10 states and left one dead
By Rafi Schwartz, The Week US Published
-
Long Covid: study shows damage to brain's 'control centre'
The Explainer Research could help scientists understand long-term effects of Covid-19 as well as conditions such as MS and dementia
By The Week UK Published
-
FDA OKs new Covid vaccine, available soon
Speed read The CDC recommends the new booster to combat the widely-circulating KP.2 strain
By Peter Weber, The Week US Published
-
Mpox: how dangerous is new health emergency?
Today's Big Question Spread of potentially deadly sub-variant more like early days of HIV than Covid, say scientists
By The Week UK Published
-
What is POTS and why is it more common now?
The explainer The condition affecting young women
By Devika Rao, The Week US Published
-
Brexit, Matt Hancock and black swans: five takeaways from Covid inquiry report
The Explainer UK was 'unprepared' for pandemic and government 'failed' citizens with flawed response, says damning report
By Harriet Marsden, The Week UK Published
-
Should masks be here to stay?
Talking Points New York Governor Kathy Hochul proposed a mask ban. Here's why she wants one — and why it may not make sense.
By Anya Jaremko-Greenwold, The Week US Published